Drug Development

Peptides Blocking HCV Genome Translation May Have Therapeutic Value

Published in Hepatitis Weekly, April 9th, 2001

A team of researchers at the Medical University of South Carolina (MUSC) and the University of Colorado Health Sciences Center is trying to identify poly-cationic peptides that bind to the internal ribosome entry site of the hepatitis C virus, thereby blocking viral translation.

They described their project at the 221st national meeting of the American Chemical Society, held March 28 - April 5, 2001. The title of their presentation was "Development of translation inhibitory peptides as precursors to antiviral agents." The lead author is Kevin S. Orwig, of MUSC.

"Translation of the HCV RNA genome provides a promising step for antiviral intervention...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry